Betahistine hydrochloride in Ménière's disease

44Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A double-blind, placebo-controlled, cross-over clinical trial was performed to assess the effect of betahistine hydrochloride (Serc) in Ménière's disease. The diagnosis was based on paroxysmal attacks of rotational vertigo, with tinnitus, and a fluctuating sensori-neural deafness, together with the results of auditory and vestibular tests. Twenty-eight patients were admitted to the trial over 3 years. Twenty-two patients completed the trial. In total, they received betahistine 32 mg daily, for a period of 16 weeks, and placebo also for the same length of time, preceded in every case by a 4-week pre-treatment period. Daily symptom score cards were kept. There was a statistically significant improvement in favour of the drug with regard to vertigo, tinnitus and deafness. Vertigo was the most responsive symptom. No adverse reactions were observed.

Cite

CITATION STYLE

APA

Frew, I. J. C., & Menon, G. N. (1976). Betahistine hydrochloride in Ménière’s disease. Postgraduate Medical Journal, 52(610), 501–503. https://doi.org/10.1136/pgmj.52.610.501

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free